The Blue Venture Fund
VC Fund
Chicago, United States
The Blue Venture Fund is a strategic investment vehicle that aims to foster innovation within the healthcare system. The Blue Venture Fund invests in emerging healthcare companies that have the potential to improve the quality of care, enhance patient experience, and reduce costs. It seeks to support companies that align with the needs andpriorities of Blue Cross Blue Shield (BCBS) member companies and their policyholders.
- Total investments:
- 101
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $10M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries The Blue Venture Fund invests in
Stages The Blue Venture Fund invests in
Countries The Blue Venture Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $50k–$14M
- Series A
- $2.4M–$35M
- Series B
- $4M–$38M
Investment Focus
Industry
- Health Care 48 (48%)
- Medical 18 (18%)
- Wellness 14 (14%)
- Software 13 (13%)
- Information Technology 11 (11%)
Stage
- Series A 25 (25%)
- Series B 21 (21%)
- Seed 12 (12%)
- Series C 11 (11%)
- Funding Round 7 (7%)
Country
- United States 59 (58%)
- United Kingdom 2 (2%)
- India 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
John Banta
Vice President of Investments; President and Managing Director
|
Vice President of Investments; President and Managing Director | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Fort Health
|
Fort Health offers a solution that provides mental health care for families. The company was founded in 2022 and is headquartered in New York, United States. | $5.5M / Seed / Nov 12, 2024 | |
Humata Health
|
Humata Health is an AI-enabled deep clinical integration that creates prior authorizations for payers and providers using AI and automation. | $25M / Series A / Jun 20, 2024 | |
Tuesday Health
|
Tuesday Health empowers lives through supportive care by easing the symptoms and stress of serious illness. | $60M / May 21, 2024 | |
|
Tuesday Health
|
Tuesday Health empowers lives through supportive care by easing the symptoms and stress of serious illness. | $60M / Series A / May 21, 2024 | |
Sempre Health
|
Sempre Health is bringing dynamic pricing to healthcare. This allows patients to afford care for longer, which directly improves clinical outcomes / quality measures while reducing utilization / cost.Patients receive texts like, “If you fill your prescription today, you’ll pay $10. If you wait until next week, this could go back up to$30.”We parse millions of prescription records to identify unique patient behaviors. We use this data to predict and seamlessly deliver the right price for the right patient to every pharmacy in the country. At the same time, we’re generating the first ever real-world dataset on patient price sensitivities and cost behaviors. | $20M / Series B / Sep 13, 2023 | |
|
Sempre Health
|
Sempre Health is bringing dynamic pricing to healthcare. This allows patients to afford care for longer, which directly improves clinical outcomes / quality measures while reducing utilization / cost.Patients receive texts like, “If you fill your prescription today, you’ll pay $10. If you wait until next week, this could go back up to$30.”We parse millions of prescription records to identify unique patient behaviors. We use this data to predict and seamlessly deliver the right price for the right patient to every pharmacy in the country. At the same time, we’re generating the first ever real-world dataset on patient price sensitivities and cost behaviors. | $20M / Series C / Sep 13, 2023 | |
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $30M / Series B / Jul 26, 2023 | |
Nest Health
|
Nest Health offers medical services that aim to minimize the stress of arranging childcare, making travel arrangements, and leaving home. The company offers a wide range of services to newborns, babies, children, teens, and adults for medical, behavioral, nutrition, and more, enabling patients to get treated at home. | $15M / Seed / Mar 23, 2023 | |
Perspectum
|
Perspectum delivers cutting-edge digital technologies that help clinicians provide better care for patients with liver disease, diabetes, and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection,diagnosis, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers, and technologists, Perspectum offers a way to manage complex health problems at scale. | $36.9M / Series C / Jan 05, 2023 | |
Onc.AI
|
Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics. The company develops a comprehensive approach to oncology diagnostics and uses deep learning to derive actionable insights into oncology treatment.It was founded in 2020 by Akshay Nanduri and Salmaan Ahmed and is based in San Carlos, California,United States. | $25M / Series A / Jan 05, 2023 | |
| See all 101 investments → | |||
Co-Investors
The Blue Venture Fund
102 deals together
Sandbox Industries
41 deals together
.406 Ventures
8 deals together
HCA Healthcare
6 deals together
Healthbox
6 deals together
HLM Venture Partners
6 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does The Blue Venture Fund invest in?
The Blue Venture Fund invests primarily in Health Care, Medical and Wellness startups, most often at Series A and Series B stage. Most of the 101 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is The Blue Venture Fund's check size?
The Blue Venture Fund typically joins rounds of $50k–$14M at Seed, $2.4M–$35M at Series A and $4M–$38M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds The Blue Venture Fund participates in.
How do I contact The Blue Venture Fund?
Public channels for The Blue Venture Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at The Blue Venture Fund?
The team at The Blue Venture Fund includes John Banta (Vice President of Investments; President and Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
